Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Autor: van Amerongen, Guido, Kanhai, Kawita, Baakman, Anne Catrien, Heuberger, Jules, Klaassen, Erica, Beumer, Tim L., Strijers, Rob L.M., Killestein, Joep, van Gerven, Joop, Cohen, Adam, Groeneveld, Geert Jan

Publikováno v: In Clinical Therapeutics September 2018 40(9):1467-1482

An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine

Autor: Baakman, Anne Catrien, Alvarez‐Jimenez, Ricardo, Rissmann, Robert, Klaassen, Erica S., Stevens, Jasper, Goulooze, Sebastiaan C., den Burger, Jeroen C. G., Swart, Eleonora L., van Gerven, Joop M. A., Groeneveld, Geert Jan

The muscarinic acetylcholine receptor antagonist scopolamine is often used for proof-of-pharmacology studies with pro-cognitive compounds. From a pharmacological point of view, it would seem more rational to use a nicotinic rather than a muscarinic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::58ab64ab93f1af4506cd479e5a2eb910
https://europepmc.org/articles/PMC5510063/

Model‐based exposure‐response analysis to quantify age related differences in the response to scopolamine in healthy subjects

Autor: Alvarez‐Jimenez, Ricardo, Groeneveld, Geert Jan, van Gerven, Joop M. A., Goulooze, Sebastiaan C., Baakman, Anne Catrien, Hay, Justin L., Stevens, Jasper

Subjects with increasing age are more sensitive to the effects of the anti-muscarinic agent scopolamine, which is used (among other indications) to induce temporary cognitive dysfunction in early phase drug studies with cognition enhancing compounds.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88474d23f9cdc484ab3cf2b0f1b7fd44
https://europepmc.org/articles/PMC5137826/

PK and PD of a nicotinic anticholinergic challenge with mecamylamine and comparison to scopolamine

Autor: Baakman, Anne Catrien, Rissmann, Robert, Groeneveld, Geert Jan

Publikováno v: In Alzheimer's & Dementia: The Journal of the Alzheimer's Association July 2013 9(4) Supplement:P805-P806

An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Autor: Baakman AC; Centre for Human Drug Research, Leiden, The Netherlands., Alvarez-Jimenez R; Centre for Human Drug Research, Leiden, The Netherlands., Rissmann R; Centre for Human Drug Research, Leiden, The Netherlands., Klaassen ES; Centre for Human Drug Research, Leiden, The Netherlands., Stevens J; Centre for Human Drug Research, Leiden, The Netherlands., Goulooze SC; Centre for Human Drug Research, Leiden, The Netherlands., den Burger JCG; Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands., Swart EL; Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands., van Gerven JMA; Centre for Human Drug Research, Leiden, The Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2017 Aug; Vol. 83 (8), pp. 1676-1687. Date of Electronic Publication: 2017 Apr 08.